Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Restructuring Costs (2022 - 2024)

Krystal Biotech's Restructuring Costs history spans 3 years, with the latest figure at $12.5 million for Q3 2024.

  • For Q3 2024, Restructuring Costs changed N/A year-over-year to $12.5 million; the TTM value through Jun 2025 reached $12.5 million, down 50.0%, while the annual FY2024 figure was $37.5 million, 200.0% up from the prior year.
  • Restructuring Costs for Q3 2024 was $12.5 million at Krystal Biotech, roughly flat from $12.5 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $25.0 million in Q1 2022 and bottomed at $12.5 million in Q1 2023.
  • The 3-year median for Restructuring Costs is $12.5 million (2023), against an average of $14.6 million.
  • The largest annual shift saw Restructuring Costs tumbled 50.0% in 2023 before it changed 0.0% in 2024.
  • A 3-year view of Restructuring Costs shows it stood at $25.0 million in 2022, then crashed by 50.0% to $12.5 million in 2023, then changed by 0.0% to $12.5 million in 2024.
  • Per Business Quant, the three most recent readings for KRYS's Restructuring Costs are $12.5 million (Q3 2024), $12.5 million (Q2 2024), and $12.5 million (Q1 2024).